Scandinavian Biopharma’s expansion requires expanded premises
During the pandemic, Scandinavian Biopharma has succeeded in completing and starting several clinical studies, developed an improved formulation for commercial launch and built production capacity together with our contract manufacturers. During the pandemic, the company has hired many new employees in research, clinical development, registration, manufacturing and sales. We continue to grow to achieve our goal of registering the world’s first vaccine against diarrhoea caused by the ETEC bacteria for children and adults in endemic countries as well as travellers to high-risk destinations.
“It is great that we are expanding the business so much that we need larger premises. It has been five years since we moved into the area, and the proximity to Hagastaden, Karolinska University Hospital and the surrounding life science cluster makes this a very attractive place for companies like us. The collaboration with Humlegården has worked very well and we are happy to be able to continue the journey together”, says Björn Sjöstrand at CEO Scandinavian Biopharma.
Scandinavian Biopharma has signed a five-year lease with real estate company Humlegården, which is the largest private property owner in the Hagalund business area. The premises in Solna have been expanded by about 160 square meters, so that the total area will be just over 720 square meters. The space is specially adapted for Scandinavian Biopharma’s operations and has a tailor-made, state of the art laboratory with a process development unit as well as a modern meeting place.
Foto: Åke E:son Lindman
